Amyloid
Alzheimer’s experts revise guidelines for amyloid, tau PET utilization
Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests should only be ordered if the results will directly impact care, like when determining treatment eligibility.
The promise of anti-amyloid therapies: A new era in Alzheimer’s treatment
The world is facing an impending tsunami as the number of people developing Alzheimer’s disease continues to grow.
Study finds no link between late-life depression, global amyloid deposition
ORLANDO, Fla. — Among a cohort of patients within the Atherosclerosis Risk in Communities study, no link was found between late-life depression and global amyloid deposition, according to a poster at the American Neurological Association.
FDA grants 510(k) clearance to amyloid imaging tool
The FDA has granted 510(k) clearance to a Centiloid scaling apparatus software for positron emission tomography-based amyloid imaging to evaluate individuals for Alzheimer’s disease-related pathology.
Depressive symptoms linked to amyloid accumulation, suggesting ties to preclinical AD
Increasing depressive symptoms among cognitively unimpaired older adults appeared significantly associated with early amyloid accumulation in brain regions involved in emotional control, according to a study published in JAMA Network Open.
VIDEO: Computerized test detects cognitive impairment, amyloid presence in preclinical AD
PHILADELPHIA — A computerized cognitive battery was effective in detecting cognitive impairment and amyloid presence in preclinical Alzheimer’s disease, James E. Galvin, MD, MPH, said in this Healio Video Perspective.
VIDEO: Phosphorylated tau assays most accurate in identifying amyloid PET status
PHILADELPHIA — In this Healio Video Perspective, Suzanne E. Schindler, MD, PhD, revealed phosphorylated tau biomarker assays were most accurate in identifying amyloid positron emission tomography status in Alzheimer’s disease.
Plasma p-tau assay highly accurate in identifying Alzheimer’s-related pathology
A plasma phosphorylated-tau217 assay demonstrated a high degree of accuracy in identifying biomarkers consistent with Alzheimer’s disease-related pathology, according to research from JAMA Neurology.
Partnership to advance investigational amyloid PET imaging biomarker
A neurotech company has announced an agreement with a radiopharmaceutical firm for the rights to manufacture an investigational imaging biomarker used in PET scans to assess the status of amyloid plaque in the brain.
Quantification of amyloid PET scans feasible, consistent with visual analysis in AD
For clinicians who treat patients with Alzheimer’s disease, quantification of amyloid positron emission tomography was feasible and possessed a high degree of concordance with visual analysis, according to a presentation at CTAD.